FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317109651> ?p ?o ?g. }

• W2317109651 abstract "Background Sarilumab is the first fully-human monoclonal antibody directed against the IL-6R and is being investigated for the treatment of RA. Patients with RA have elevated tissue turnover at sites of inflammation, resulting from increased activity of proteases, including matrix metalloproteinase (MMP). MMP-cleaved fragments of collagen type 1 (C1M), collagen type 2 (C2M), collagen type 3 (C3M), and C-reactive protein (CRPM) are elevated in sera from patients with RA and reductions may be associated with treatment response. Indeed, the C1M neo-epitope has been recently identified as a potentially prognostic biomarker of bone erosion. Objectives The objective of this study was to determine whether sarilumab reduces the levels of serum biomarkers related to synovial inflammation and joint damage in patients with RA. Methods MOBILITY part A was the dose-ranging phase 2 portion of the MOBILITY trial of subcutaneous sarilumab in patients with active RA treated with concomitant methotrexate (MTX). Sera were collected at baseline, 2 weeks, and 12 weeks from patients randomized to treatment with MTX+placebo (Pbo), MTX+sarilumab 150 mg q2w, or MTX+sarilumab 200 mg q2w. C1M, C2M, C3M and CRPM were analyzed by ELISA. Results Baseline levels of each biomarker were similar among treatment groups. Sarilumab treatment at both doses resulted in marked reduction in levels of C1M, C2M, C3M and CRPM from baseline at 2 weeks (Table, percent change from baseline ± SE) and suppression of each marker was maintained at 12 weeks (data not shown). In contrast, in the MTX+Pbo group there was no significant decrease in these biomarkers at both 2 and 12 weeks. Observed AEs were similar to those reported with other IL-6 inhibitors. Conclusions Sarilumab treatment in patients with RA resulted in significant dose-dependent reduction in MMP-generated neo-epitope biomarkers related to joint and tissue turnover. The most dramatic reduction associated with sarilumab treatment was observed with the C1M neo-epitope, a potentially prognostic biomarker of structural damage (ref). Additional studies are needed to determine if reduction of MMP-cleaved fragments, such as C1M or CRPM, predict clinical and/or radiographic responses (bone erosion and/or joint space narrowing) in patients treated with sarilumab. References AS Siebuhr et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Research & Therapy 2013, 15:R86 doi:10.1186/ar4266. Acknowledgements Sponsored by Sanofi and Regeneron Pharmaceuticals Inc. (NCT01061736). Disclosure of Interest : S. Fiore Shareholder of: Sanofi US, Employee of: Sanofi US, A. Boyapati Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., S. Hamon Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., J. van Adelsberg Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., M. Liu Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., J. Hamilton Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc. DOI 10.1136/annrheumdis-2014-eular.3852" @default.
• W2317109651 created "2016-06-24" @default.
• W2317109651 creator A5004289717 @default.
• W2317109651 creator A5019163181 @default.
• W2317109651 creator A5028202538 @default.
• W2317109651 creator A5032531829 @default.
• W2317109651 creator A5042703700 @default.
• W2317109651 creator A5064777057 @default.
• W2317109651 date "2014-06-01" @default.
• W2317109651 modified "2023-09-26" @default.
• W2317109651 title "THU0275 IL-6 Receptor (IL-6R) Blockade with Sarilumab Reduced Circulating Markers Related to Synovial Inflammation and Structural Damage in Patients with Rheumatoid Arthritis (RA) in A Phase 2 Study" @default.
• W2317109651 doi "https://doi.org/10.1136/annrheumdis-2014-eular.3852" @default.
• W2317109651 hasPublicationYear "2014" @default.
• W2317109651 type Work @default.
• W2317109651 sameAs 2317109651 @default.
• W2317109651 citedByCount "0" @default.
• W2317109651 crossrefType "journal-article" @default.
• W2317109651 hasAuthorship W2317109651A5004289717 @default.
• W2317109651 hasAuthorship W2317109651A5019163181 @default.
• W2317109651 hasAuthorship W2317109651A5028202538 @default.
• W2317109651 hasAuthorship W2317109651A5032531829 @default.
• W2317109651 hasAuthorship W2317109651A5042703700 @default.
• W2317109651 hasAuthorship W2317109651A5064777057 @default.
• W2317109651 hasConcept C126322002 @default.
• W2317109651 hasConcept C185592680 @default.
• W2317109651 hasConcept C203014093 @default.
• W2317109651 hasConcept C2776914184 @default.
• W2317109651 hasConcept C2777575956 @default.
• W2317109651 hasConcept C2781197716 @default.
• W2317109651 hasConcept C55493867 @default.
• W2317109651 hasConcept C71924100 @default.
• W2317109651 hasConcept C90924648 @default.
• W2317109651 hasConceptScore W2317109651C126322002 @default.
• W2317109651 hasConceptScore W2317109651C185592680 @default.
• W2317109651 hasConceptScore W2317109651C203014093 @default.
• W2317109651 hasConceptScore W2317109651C2776914184 @default.
• W2317109651 hasConceptScore W2317109651C2777575956 @default.
• W2317109651 hasConceptScore W2317109651C2781197716 @default.
• W2317109651 hasConceptScore W2317109651C55493867 @default.
• W2317109651 hasConceptScore W2317109651C71924100 @default.
• W2317109651 hasConceptScore W2317109651C90924648 @default.
• W2317109651 hasLocation W23171096511 @default.
• W2317109651 hasOpenAccess W2317109651 @default.
• W2317109651 hasPrimaryLocation W23171096511 @default.
• W2317109651 hasRelatedWork W2166830441 @default.
• W2317109651 hasRelatedWork W2313823025 @default.
• W2317109651 hasRelatedWork W2318382810 @default.
• W2317109651 hasRelatedWork W2318533659 @default.
• W2317109651 hasRelatedWork W2321953976 @default.
• W2317109651 hasRelatedWork W2324994705 @default.
• W2317109651 hasRelatedWork W2331697160 @default.
• W2317109651 hasRelatedWork W2527818415 @default.
• W2317109651 hasRelatedWork W2550796645 @default.
• W2317109651 hasRelatedWork W2556982966 @default.
• W2317109651 hasRelatedWork W2755317643 @default.
• W2317109651 hasRelatedWork W2755664297 @default.
• W2317109651 hasRelatedWork W2755714531 @default.
• W2317109651 hasRelatedWork W2755738890 @default.
• W2317109651 hasRelatedWork W2765813781 @default.
• W2317109651 hasRelatedWork W2790022206 @default.
• W2317109651 hasRelatedWork W2910679563 @default.
• W2317109651 hasRelatedWork W2952482476 @default.
• W2317109651 hasRelatedWork W3113314553 @default.
• W2317109651 hasRelatedWork W2980727182 @default.
• W2317109651 isParatext "false" @default.
• W2317109651 isRetracted "false" @default.
• W2317109651 magId "2317109651" @default.
• W2317109651 workType "article" @default.